









Markets
/
Stocks
/
nasdaq-hcwb
/

HCW Biologics Inc

HCWB

1.040USD

+0.050+5.05%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.73MMarket Cap

LossP/E TTM



HCW Biologics Inc

1.040

+0.050+5.05%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of HCW Biologics Inc

Currency: USD Updated: 2026-02-06

Key Insights

HCW Biologics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 193 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

HCW Biologics Inc's Score

Industry at a Glance

Industry Ranking

193 / 392

Overall Ranking

373 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

HCW Biologics Inc Highlights

StrengthsRisks

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.57M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.57M.

Overvalued

The company’s latest PE is -0.07, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 125.21K shares, increasing 14.47% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.43K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.68.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

8.000

Target Price

+661.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of HCW Biologics Inc is 5.12, ranking 380 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 15.61K, representing a year-over-year decrease of 96.34%, while its net profit experienced a year-over-year decrease of 16.71%.

Score

Industry at a Glance

Previous score

5.12

Change



Financials

3.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.92

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

HCW Biologics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of HCW Biologics Inc is 8.93, ranking 4 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.07, which is -6.71% below the recent high of -0.07 and -358764.30% above the recent low of -267.35.

Score

Industry at a Glance

Previous score

8.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 193/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of HCW Biologics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 35.00, with a high of 35.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

8.000

Target Price

+661.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

HCW Biologics Inc

HCWB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of HCW Biologics Inc is 2.61, ranking 374 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.47 and the support level at 0.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.50

Change

0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Neutral

RSI(14)

35.568

Neutral

STOCH(KDJ)(9,3,3)

13.026

Oversold

ATR(14)

0.131

Low Volatility

CCI(14)

-109.569

Sell

Williams %R

88.406

Oversold

TRIX(12,20)

-1.010

Sell

StochRSI(14)

56.662

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.070

Sell

MA10

1.134

Sell

MA20

1.203

Sell

MA50

1.472

Sell

MA100

2.564

Sell

MA200

4.033

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of HCW Biologics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.63%, representing a quarter-over-quarter increase of 170.01%. The largest institutional shareholder is The Vanguard, holding a total of 15.43K shares, representing 0.57% of shares outstanding, with 5.53% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Wong (Hing C)

509.96K

+27.06%

DRW Securities, LLC

83.44K

Byam (Rebecca)

43.01K

+24.49%

Garrett (Scott T)

25.50K

+280.84%

The Vanguard Group, Inc.

Star Investors

15.43K

Geode Capital Management, L.L.C.

11.00K

Golden State Wealth Management, LLC

10.00K

Flowers (Lee)

5.72K

+20.23%

Winer (Gary M)

4.08K

+858.82%

Greene (Rick Scott)

2.07K

+87.14%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of HCW Biologics Inc is 1.40, ranking 319 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.72. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.